Northwestern University

Company

Related News

BioNTech, BioLineRx Unveil Clinical Data at ASCO 2026

BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.

Related Clinical Trials

NCT ID Title Status Phase
NCT07612475

Type 1 Diabetes Screening

NOT_YET_RECRUITING
NCT07610655

Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression

RECRUITING NA
NCT07607613

Parents and Babies Pilot

NOT_YET_RECRUITING NA
NCT07604272

Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

NOT_YET_RECRUITING PHASE1
NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

NOT_YET_RECRUITING PHASE1/PHASE2
NCT07594548

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NOT_YET_RECRUITING PHASE1
NCT07586046

Defining the Ablative Dose for Y-90 TARE

NOT_YET_RECRUITING PHASE2
NCT07580404

Emsella for Reducing tSUI After HOLEP

NOT_YET_RECRUITING NA
NCT07580391

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

ACTIVE_NOT_RECRUITING NA
NCT07564388

Cochlear-Implant-Performance-Prediction

ENROLLING_BY_INVITATION NA